

# HOLOGIC<sup>®</sup>

The Science of Sure



## accessa<sup>®</sup>

BRIDGING THE GAP  
between **Medical Management** and  
Major Surgery for **Uterine Fibroids**


[gynsurgicalsolutions.com](http://gynsurgicalsolutions.com)

Brandi | Procedure Date: December 2019

Andrea | Procedure Date: January 2020



# BRIDGING THE GAP BETWEEN FIBROID TREATMENT OPTIONS



*This chart is representative only, to be used in shared decision making between patients and physicians. It is based on physician and patient input. The invasiveness and time to return to daily life of different procedures is dependent on numerous factors. This chart is not intended to be a representation of a single study or clinical data.*




The Acessa® procedure (Lap-RFA)

# Visualize | Deploy | Treat

THE **FIRST** AND **ONLY** TO INCORPORATE:

- 1 Laparoscopic Ultrasound
- 2 Guidance Mapping
- 3 Radiofrequency Ablation








# Visualize | Deploy | Treat

## Laparoscopic Ultrasound

Increased visibility with combined laparoscopic and ultrasound view

- ✓ LUS identified 1.5 - 2.0x more fibroids than TVUS or MRI<sup>1</sup>
- ✓ Ability to see fibroids potentially missed in standard myomectomy



Source:

<sup>1</sup> Levine, D. J., Berman, J. M., Harris, M., Chudnoff, S. G., Whaley, F. S., & Palmer, S. L. (2013). Sensitivity of Myoma Imaging Using Laparoscopic Ultrasound Compared with Magnetic Resonance Imaging and Transvaginal Ultrasound. *Journal of Minimally Invasive Gynecology*, 20(6), 770-774. doi: 10.1016/j.jmig.2013.04.015

© 2021 Hologic, Inc. All Rights Reserved. PRE-01459 Rev 001 Rev 001


**HOLOGIC**®



# Visualize | Deploy | Treat

## Guidance Mapping

- ✓ Heightened precision
- ✓ Confirms safe and proper placement of the Acessa handpiece
- ✓ Provides simple targeting and visualization cues






— Visualize | **Deploy** | **Treat**

## Radiofrequency Ablation

- ✓ Controlled monopolar RF energy with visualization of treatment area
- ✓ Designed to target only fibroid tissue without harming healthy uterine tissue<sup>2</sup>
- ✓ No laparoscopic suturing

<sup>2</sup> SG Chudnoff, et al. Outpatient Procedure for the Treatment and Relief of Symptomatic Uterine Myomas. *Obstetrics and Gynecology*, 2013;121(5):1075-82.



EXTENSIVE



ENHANCED



EFFECTIVE



ENGAGED









OPTIMIZED TECHNOLOGY  
FOR MORE



# COMPLETE FIBROID TREATMENT

Easily locate and target nearly all fibroids,  
including intramural<sup>3</sup>

Addresses symptoms including heavy  
bleeding and bulk<sup>3</sup>



<sup>3</sup> SG Chudnoff, et al. Outpatient Procedure for the Treatment and Relief of Symptomatic Uterine Myomas. Obstetrics and Gynecology, 2013;121(5):1075-82.

-  Treat using the Acessa<sup>®</sup> procedure
-  Treat using MyoSure<sup>®</sup>



# CARE FOR MORE PATIENTS

BY OFFERING MORE  
UTERINE SPARING OPTIONS



Appeal to patients who are seeking an alternative to hysterectomy

Offer personalized and complete treatment with concomitant procedures





# PROVIDE RELIEF WITH LOW REINTERVENTION

**11%**

cumulative 3 year  
reintervention rate<sup>4</sup>

**94%**

of women said the  
procedure helped  
with their symptoms<sup>6</sup>

**103  
mL**

decrease in  
menstrual blood  
loss from baseline<sup>6</sup>  
(by 12 months)

**4-5  
DAYS**

Patients are back to  
work in 4-5 days<sup>6</sup>

Patients go home the same day,  
typically leaves on NSAIDS/Tylenol

Lowest complication rate and  
intraoperative blood loss compared to  
traditional fibroid procedures<sup>5</sup>

**45%**

volumetric reduction  
of fibroid size<sup>6</sup>  
(by 12 months)

Sources:

<sup>4</sup> Berman, J., Guido, R., Garza, L. J., Robles, P. R., Whaley, F., & Chudnoff, S. (2014). Three Years' Outcome from the Halt Trial: A Prospective Analysis of Radiofrequency Volumetric Thermal Ablation of Myomas. *Journal of Minimally Invasive Gynecology*, 21(6). doi: 10.1016/j.jmig.2014.08.072 <sup>5</sup> Havryliuk, Y., Setton, R., Carlow, J. J., & Shaktman, B. D. (2017). Symptomatic Fibroid Management: Systematic Review of the Literature. *JSL: Journal of the Society of Laparoendoscopic Surgeons*, 21(3). Doi: <sup>6</sup> SG Chudnoff, et al. Outpatient Procedure for the Treatment and Relief of Symptomatic Uterine Myomas. *Obstetrics and Gynecology*, 2013;121(5):1075-82.



UNPARALLELED

# SUPPORT

FROM START TO FINISH

Benefit from an  
EXTENSIVE TRAINING PROGRAM

Gain access to a first in class  
INSURANCE SUPPORT TEAM

Promote Acessa locally with in-depth  
MARKETING TOOLS



ENGAGED

Thank you



#### IMPORTANT SAFETY INFORMATION

The ACESSA ProVu system is indicated for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The ACESSA ProVu system is contraindicated for patients who are not candidates for laparoscopic surgery and/or patients with a uterus adherent to pelvic tissue or viscera. The ACESSA ProVu system's guidance system is not intended for diagnostic use. Please read all instructions for use of the ACESSA ProVu system prior to its use. Safe and effective electrosurgery is dependent not only on equipment design but also on factors under control of the operator. Rare but serious risks include, but are not limited to, skin burns, mild inter-operative bleeding, post-procedural discomfort (cramping, pelvic pain), infection, vaginal bleeding, blood loss and complications related to laparoscopy and or general anesthesia. If you or someone you know has possibly experienced a side effect when using our product please contact your physician. Insufficient data exists on which to evaluate the safety and effectiveness of the ACESSA ProVu system in women who plan future pregnancy, therefore the ACESSA ProVu system is not recommended for women who are planning future pregnancy.

PRE-01472 Rev 001 ©2021 Hologic, Inc. All Rights Reserved. Hologic, ACESSA ProVu, MyoSure, The Science of Sure and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

**HOLOGIC®**

[gynsurgicalsolutions.com](https://gynsurgicalsolutions.com)



